Barclays Boosts Bausch Health Companies (NYSE:BHC) Price Target to $29.00

Bausch Health Companies (NYSE:BHC) had its price objective increased by Barclays from $28.00 to $29.00 in a research report report published on Monday morning, The Fly reports. The firm currently has an overweight rating on the stock.

Other research analysts also recently issued reports about the stock. Citigroup decreased their price target on shares of Bausch Health Companies from $27.00 to $26.00 and set a buy rating on the stock in a research note on Monday, August 10th. ValuEngine downgraded shares of Bausch Health Companies from a sell rating to a strong sell rating in a research note on Thursday, July 2nd. Royal Bank of Canada lifted their price target on shares of Bausch Health Companies from $23.00 to $26.00 and gave the stock a sector perform rating in a research note on Monday, August 10th. Zacks Investment Research downgraded shares of Bausch Health Companies from a hold rating to a strong sell rating and set a $15.00 price target on the stock. in a research note on Tuesday, October 13th. Finally, Bank of America raised shares of Bausch Health Companies from an underperform rating to a neutral rating and lifted their price target for the stock from $16.00 to $19.00 in a research note on Thursday, September 17th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $28.94.

Shares of Bausch Health Companies stock opened at $16.85 on Monday. The firm has a market capitalization of $5.98 billion, a PE ratio of -2.91, a price-to-earnings-growth ratio of 2.49 and a beta of 1.08. The company has a current ratio of 1.12, a quick ratio of 0.86 and a debt-to-equity ratio of 44.61. Bausch Health Companies has a 12 month low of $11.15 and a 12 month high of $31.97. The business’s 50-day moving average price is $16.58 and its 200-day moving average price is $17.46.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Thursday, August 6th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.66 by ($0.20). The firm had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.79 billion. Bausch Health Companies had a positive return on equity of 104.13% and a negative net margin of 25.19%. The firm’s quarterly revenue was down 22.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.07 EPS. As a group, analysts predict that Bausch Health Companies will post 3.63 earnings per share for the current fiscal year.

In other Bausch Health Companies news, insider William D. Humphries sold 5,667 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $16.17, for a total transaction of $91,635.39. Following the transaction, the insider now directly owns 235,035 shares of the company’s stock, valued at approximately $3,800,515.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 12.14% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of BHC. FMR LLC boosted its holdings in shares of Bausch Health Companies by 14.4% during the 1st quarter. FMR LLC now owns 312,264 shares of the company’s stock valued at $7,704,000 after buying an additional 39,276 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its holdings in shares of Bausch Health Companies by 123.0% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 202,426 shares of the company’s stock valued at $5,000,000 after buying an additional 111,654 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Bausch Health Companies by 67.4% during the 1st quarter. Alliancebernstein L.P. now owns 54,982 shares of the company’s stock valued at $852,000 after buying an additional 22,130 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Bausch Health Companies by 12.7% during the 1st quarter. Geode Capital Management LLC now owns 497,780 shares of the company’s stock valued at $7,667,000 after buying an additional 56,204 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Bausch Health Companies by 57.9% during the 1st quarter. Wells Fargo & Company MN now owns 268,735 shares of the company’s stock valued at $4,165,000 after buying an additional 98,544 shares in the last quarter. 64.46% of the stock is currently owned by institutional investors and hedge funds.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: What are earnings reports?

The Fly

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.